Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Ubrogepant · Ubrelvy

Small molecule · Antagonist of calcitonin gene-related peptide receptor (CALCRL) · developed by Abbvie

Approved FDA, Dec 2019
ABBV Developer
1 Registered trials

What is Ubrogepant?

Ubrogepant is a small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist that blocks CGRP signaling at its receptor. It is used for the acute treatment of migraine with or without aura in adults.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Ubrelvy
Drug type
Small molecule
Targets
calcitonin gene-related peptide receptor (CALCRL)
Mechanism
Antagonist of calcitonin gene-related peptide receptor (CALCRL)
Therapy area
Neurology
Developer
Abbvie (ABBV)
FDA status
Approved as Ubrelvy (December 23, 2019), NDA211765 · FDA label
UNII
AD0O8X2QJR

✅ FDA-approved uses

From the indications section of the FDA label (version of Sep 29, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07680686 Phase 1 Healthy Volunteer Completed ABBV

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Healthy Volunteer

Other drugs acting on CALCRL

More from Abbvie

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the ABBV page.

Follow ABBV, the company behind Ubrogepant

See ABBV's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ABBV catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.